scholarly journals Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome

2010 ◽  
Vol 5 (1) ◽  
Author(s):  
Steve Heymann ◽  
Suzette Delaloge ◽  
Arslane Rahal ◽  
Olivier Caron ◽  
Thierry Frebourg ◽  
...  
Author(s):  
M. Gabriela Kuba ◽  
Susan C. Lester ◽  
Teresa Bowman ◽  
Samantha M. Stokes ◽  
Krishan L. Taneja ◽  
...  

Author(s):  
LN Gallardo-Alvarado ◽  
DF Cantu-De Leon ◽  
T Tusie-Luna ◽  
I Tusie-Luna ◽  
J Diaz-Chavez ◽  
...  

1993 ◽  
Vol 79 (5) ◽  
pp. 291-296 ◽  
Author(s):  
Simon A. Smith ◽  
Bruce A.J. Ponder

The isolation of genes that predispose to familial disease is an important goal in cancer research. The identification of such genes « opens up » the possibility of genetic diagnosis in families so that individuals who are at risk of cancer through inheriting a predisposing mutation can be Identified. Genes that are involved in familial cancer syndromes may also be important in the pathogenesis of sporadic forms of the disease, which are often more common. In the search for genes that predispose to familial breast and ovarian cancer much recent progress has been made. A locus on the long arm of chromosome 17, in the interval 17q12-21, has been identified by genetic linkage, and appears to be responsible for disease in approximately 40 % of breast cancer families and most families that contain breast and ovarian cancer. The region containing this locus, which has been called BRCA1, has been narrowed to a 3-4 cM interval defined by THRA1, the thyroid hormone receptor locus alpha, and D17S183, an anonymous microsatellite polymorphism. Loci other than BRCA1 that have been identified appear not only to predispose to breast and/or ovarian tumors, but to tumors at other sites too. A new locus has been identified on chromosome 2 which is linked to hereditary non-polyposis colorectal cancer (HNPCC). Families with HNPCC are also at risk of endometrial cancer and tumors of the ovary, amongst other cancer sites. Finally, mutations in the p53 gene are inherited in families with Li-Fraumeni syndrome, a rare cancer syndrome predisposing to breast tumors, sarcomas, leukemia and other cancers. Li-Fraumeni syndrome is also the only inherited cancer syndrome that predisposes at least in part to breast cancer where the actual predisposing gene is known. For the other cancer syndromes, the cloning of the predisposing genes is eagerly awaited.


2019 ◽  
Vol 19 (1) ◽  
pp. 47-53 ◽  
Author(s):  
Vanessa Petry ◽  
Renata Colombo Bonadio ◽  
Allyne Queiroz Carneiro Cagnacci ◽  
Luiz Antonio Leite Senna ◽  
Roberta do Nascimento Galvão Campos ◽  
...  

2017 ◽  
Vol 30 (1) ◽  
pp. e5-e6
Author(s):  
Allison M. Jay ◽  
Anthony S. Hamame ◽  
Carrie Dul ◽  
Cheryl Wesen

BMC Cancer ◽  
2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Karin Kast ◽  
Mechthild Krause ◽  
Markus Schuler ◽  
Katrin Friedrich ◽  
Barbara Thamm ◽  
...  

2021 ◽  
Vol 22 (12) ◽  
pp. 6345
Author(s):  
Yaxuan Liu ◽  
Olga Axell ◽  
Tom van Leeuwen ◽  
Robert Konrat ◽  
Pedram Kharaziha ◽  
...  

Rare germline pathogenic TP53 missense variants often predispose to a wide spectrum of tumors characterized by Li-Fraumeni syndrome (LFS) but a subset of variants is also seen in families with exclusively hereditary breast cancer (HBC) outcomes. We have developed a logistic regression model with the aim of predicting LFS and HBC outcomes, based on the predicted effects of individual TP53 variants on aspects of protein conformation. A total of 48 missense variants either unique for LFS (n = 24) or exclusively reported in HBC (n = 24) were included. LFS-variants were over-represented in residues tending to be buried in the core of the tertiary structure of TP53 (p = 0.0014). The favored logistic regression model describes disease outcome in terms of explanatory variables related to the surface or buried status of residues as well as their propensity to contribute to protein compactness or protein-protein interactions. Reduced, internally validated models discriminated well between LFS and HBC (C-statistic = 0.78−0.84; equivalent to the area under the ROC (receiver operating characteristic) curve), had a low risk for over-fitting and were well calibrated in relation to the known outcome risk. In conclusion, this study presents a phenotypic prediction model of LFS and HBC risk for germline TP53 missense variants, in an attempt to provide a complementary tool for future decision making and clinical handling.


Author(s):  
Yukako SHIBATA ◽  
Akimitsu YAMADA ◽  
Sadatoshi SUGAE ◽  
Haruka HAMANOUE ◽  
Shinya YAMAMOTO ◽  
...  

2018 ◽  
Vol 20 (1) ◽  
Author(s):  
Judith Penkert ◽  
Gunnar Schmidt ◽  
Winfried Hofmann ◽  
Stephanie Schubert ◽  
Maximilian Schieck ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document